119 related articles for article (PubMed ID: 14681897)
1. Minocycline is protective in a mouse model of Huntington's disease.
Hersch S; Fink K; Vonsattel JP; Friedlander RM
Ann Neurol; 2003 Dec; 54(6):841; author reply 842-3. PubMed ID: 14681897
[No Abstract] [Full Text] [Related]
2. Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease.
Diguet E; Rouland R; Tison F
Ann Neurol; 2003 Dec; 54(6):841-2. PubMed ID: 14681898
[No Abstract] [Full Text] [Related]
3. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.
Chen M; Ona VO; Li M; Ferrante RJ; Fink KB; Zhu S; Bian J; Guo L; Farrell LA; Hersch SM; Hobbs W; Vonsattel JP; Cha JH; Friedlander RM
Nat Med; 2000 Jul; 6(7):797-801. PubMed ID: 10888929
[TBL] [Abstract][Full Text] [Related]
4. Revisiting safety of minocycline as neuroprotection in Huntington's disease.
Reynolds N
Mov Disord; 2007 Jan; 22(2):292. PubMed ID: 17083098
[No Abstract] [Full Text] [Related]
5. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease.
Diguet E; Fernagut PO; Wei X; Du Y; Rouland R; Gross C; Bezard E; Tison F
Eur J Neurosci; 2004 Jun; 19(12):3266-76. PubMed ID: 15217383
[TBL] [Abstract][Full Text] [Related]
6. Clinical potential of minocycline for neurodegenerative disorders.
Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
[TBL] [Abstract][Full Text] [Related]
7. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease.
Ryu JK; Choi HB; McLarnon JG
Neuroscience; 2006 Sep; 141(4):1835-48. PubMed ID: 16809003
[TBL] [Abstract][Full Text] [Related]
8. Minocycline in Huntington's disease: a pilot study.
Thomas M; Ashizawa T; Jankovic J
Mov Disord; 2004 Jun; 19(6):692-5. PubMed ID: 15197710
[TBL] [Abstract][Full Text] [Related]
9. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease.
Thomas M; Le WD; Jankovic J
Clin Neuropharmacol; 2003; 26(1):18-23. PubMed ID: 12567160
[No Abstract] [Full Text] [Related]
10. Citicoline is not protective in experimental models of Huntington's disease.
Mievis S; Levivier M; Vassart G; Brotchi J; Ledent C; Blum D
Neurobiol Aging; 2007 Dec; 28(12):1944-6. PubMed ID: 17064815
[TBL] [Abstract][Full Text] [Related]
11. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
[TBL] [Abstract][Full Text] [Related]
12. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
[TBL] [Abstract][Full Text] [Related]
13. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase.
Bailey CD; Johnson GV
Neurobiol Aging; 2006 Jun; 27(6):871-9. PubMed ID: 15896882
[TBL] [Abstract][Full Text] [Related]
14. Maintained improvement with minocycline of a patient with advanced Huntington's disease.
Denovan-Wright EM; Devarajan S; Dursun SM; Robertson HA
J Psychopharmacol; 2002 Dec; 16(4):393-4. PubMed ID: 12503842
[TBL] [Abstract][Full Text] [Related]
15. Experimental therapeutics in transgenic mouse models of Huntington's disease.
Beal MF; Ferrante RJ
Nat Rev Neurosci; 2004 May; 5(5):373-84. PubMed ID: 15100720
[No Abstract] [Full Text] [Related]
16. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
[TBL] [Abstract][Full Text] [Related]
17. Rise and fall of minocycline in neuroprotection: need to promote publication of negative results.
Diguet E; Gross CE; Tison F; Bezard E
Exp Neurol; 2004 Sep; 189(1):1-4. PubMed ID: 15296829
[TBL] [Abstract][Full Text] [Related]
18. Regional differences in the neuroprotective effect of minocycline in a mouse model of global forebrain ischemia.
Cho KO; Kim SK; Cho YJ; Sung KW; Kim SY
Life Sci; 2007 May; 80(22):2030-5. PubMed ID: 17408699
[TBL] [Abstract][Full Text] [Related]
19. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia.
Levkovitz Y; Levi U; Braw Y; Cohen H
Brain Res; 2007 Jun; 1154():154-62. PubMed ID: 17488642
[TBL] [Abstract][Full Text] [Related]
20. Impact of minocycline on neurodegenerative diseases in rodents: a meta-analysis.
Li C; Yuan K; Schluesener H
Rev Neurosci; 2013; 24(5):553-62. PubMed ID: 24077620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
